Previous Close | 0.1450 |
Open | 0.1400 |
Bid | 0.1400 x N/A |
Ask | 0.1500 x N/A |
Day's Range | 0.1400 - 0.1450 |
52 Week Range | 0.1300 - 0.3250 |
Volume | |
Avg. Volume | 102,176 |
Market Cap | 11.439M |
Beta (5Y Monthly) | 1.94 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | May 24, 2017 |
1y Target Est | N/A |
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today provided details on preliminary estimated revenues and margins from April and May 2024, the first two months of the second quarter. Mike Seckler, Chief Executive Officer of the Company, will also hold a call to update shareholders on the first quarter financials, second quarter progress and future plans of the Company. Revenue Growth Update for Q2 2024 For April and May 2024,
Posting Q1 Financials, Provides Updates on Strong Q2NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today reported continued progress on its turn-around plan. Evome has grown revenue at its core business unit, Biodex Medical Systems, Inc. (“Biodex”), while reducing total debt significantly for the third straight quarter. The Company announced it generated 100% revenue growth in its Biodex business unit in April 2024 compared to J
NEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc (the “Company” or “Evome”) highlighted the strengthening credit relationship with Pathward, N.A. (“Pathward”), the Company’s senior lender. As the Company works to sell non-core business units to reduce acquisition debt in an effort to improve operational profitability, Pathward provides working capital to fuel revenue growth of the Company’s new Biodex products. Pathward has featured the strong and growing relationship